Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-10-01 Sale | 2026-10-02 9:30 pm | Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks | 28,933 | $91.03 | $2,633,902 | 485,323 (Direct) | View |
| 2026-10-01 Sale | 2026-10-02 9:29 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 15,000 | $92.01 | $1,380,105 | 537,540 (Direct) | View |
| 2026-09-30 Sale | 2026-10-02 9:29 pm | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 25,000 | $90.47 | $2,261,831 | 711,976 (Direct) | View |
| 2026-09-01 Sale | 2026-09-03 9:34 pm | Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks | 28,399 | $87.35 | $2,480,529 | 1,026,067 (Direct) | View |
| 2026-09-01 Sale | 2026-09-03 9:33 pm | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 25,732 | $88.75 | $2,283,821 | 417,119 (Direct) | View |
| 2026-09-01 Sale | 2026-09-03 9:33 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 15,000 | $87.29 | $1,309,410 | 552,540 (Direct) | View |
| 2026-08-07 Sale | 2026-08-10 9:31 pm | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 23,000 | $104.53 | $2,404,190 | 54,360 (Indirect Direct) | View |
| 2026-08-03 Sale | 2026-08-05 9:32 pm | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $95.57 | $716,771 | 442,851 (Direct) | View |
| 2026-08-03 Sale | 2026-08-05 9:31 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 15,000 | $95.51 | $1,432,705 | 567,540 (Direct) | View |
| 2026-07-01 Sale | 2026-07-02 9:33 pm | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $87.74 | $658,040 | 450,351 (Direct) | View |
| 2026-07-01 Sale | 2026-07-02 9:33 pm | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 8,334 | $87.7 | $730,896 | 305,000 (Direct) | View |
| 2026-07-01 Sale | 2026-07-02 9:32 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 15,000 | $87.69 | $1,315,346 | 582,540 (Direct) | View |
| 2026-06-25 Sale | 2026-06-26 9:31 pm | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 15,000 | $87.13 | $1,307,000 | 457,851 (Direct) | View |
| 2026-06-23 Sale | 2026-06-23 9:56 pm | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 4,684,781 | $85.31 | $399,658,667 | 1,158,121 (Indirect) | View |
| 2026-06-22 Sale | 2026-06-23 9:32 pm | Spyre Therapeutics Inc. | SYRE | HENDERSON MICHAEL THOMAS Director | 20,000 | $100 | $2,000,000 | 68,606 (Direct) | View |
| 2026-06-03 Sale | 2026-06-03 9:32 pm | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 8,333 | $75 | $624,975 | 313,334 (Direct) | View |
| 2026-06-01 Sale | 2026-06-03 9:31 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 15,000 | $70.43 | $1,056,486 | 597,540 (Direct) | View |
| 2026-06-01 Sale | 2026-06-03 9:30 pm | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $71.06 | $532,937 | 472,851 (Direct) | View |
| 2026-05-08 Sale | 2026-05-08 9:31 pm | Spyre Therapeutics Inc. | SYRE | HENDERSON MICHAEL THOMAS Director | 80,000 | $74.4 | $5,952,050 | 88,606 (Direct) | View |
| 2026-05-01 Sale | 2026-05-01 9:35 pm | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 12,500 | $71.37 | $892,125 | 480,351 (Direct) | View |
| 2026-05-01 Sale | 2026-05-01 9:34 pm | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 78,333 | $71.5 | $5,600,701 | 321,667 (Direct) | View |
| 2026-05-01 Sale | 2026-05-01 9:34 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 15,000 | $71.37 | $1,070,507 | 612,540 (Direct) | View |
| 2026-04-01 Sale | 2026-04-03 9:30 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 15,000 | $49.33 | $739,912 | 627,540 (Direct) | View |
| 2026-04-01 Sale | 2026-04-03 9:30 pm | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 7,958 | $50 | $397,900 | 87,542 (Direct) | View |
| 2026-04-01 Sale | 2026-04-03 9:29 pm | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $49.34 | $370,076 | 492,851 (Direct) | View |
| 2026-03-03 Sale | 2026-03-03 9:32 pm | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 2,500 | $40.65 | $101,620 | 500,351 (Direct) | View |
| 2026-03-02 Sale | 2026-03-03 9:31 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 15,000 | $42.19 | $632,866 | 642,540 (Direct) | View |
| 2026-02-02 Sale | 2026-02-04 9:33 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 15,000 | $32.8 | $492,045 | 657,540 (Direct) | View |
| 2026-01-02 Sale | 2026-01-06 9:36 pm | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 15,000 | $30.68 | $460,134 | 671,907 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-10-01 Exercise | 2026-10-02 9:30 pm | N/A 2033-09-01 | Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks | 28,933 | $0 | 485,323 (Direct) | View |
| 2026-10-01 Exercise | 2026-10-02 9:30 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks | 28,933 | $14.5 | 485,323 (Direct) | View |
| 2026-09-30 Exercise | 2026-10-02 9:29 pm | N/A 2033-09-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 25,000 | $0 | 711,976 (Direct) | View |
| 2026-09-30 Exercise | 2026-10-02 9:29 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 25,000 | $14.5 | 711,976 (Direct) | View |
| 2026-09-01 Exercise | 2026-09-03 9:34 pm | N/A 2033-09-01 | Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks | 28,399 | $0 | 1,026,067 (Direct) | View |
| 2026-09-01 Exercise | 2026-09-03 9:34 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks | 28,399 | $14.5 | 1,026,067 (Direct) | View |
| 2026-09-01 Exercise | 2026-09-03 9:33 pm | N/A 2033-09-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $0 | 417,119 (Direct) | View |
| 2026-09-01 Exercise | 2026-09-03 9:33 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $14.5 | 417,119 (Direct) | View |
| 2026-08-07 Exercise | 2026-08-10 9:31 pm | N/A 2033-11-22 | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 5,000 | $0 | 54,360 (Direct) | View |
| 2026-08-07 Exercise | 2026-08-10 9:31 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 5,000 | $10.39 | 54,360 (Direct) | View |
| 2026-08-03 Exercise | 2026-08-05 9:32 pm | N/A 2033-09-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $0 | 442,851 (Direct) | View |
| 2026-08-03 Exercise | 2026-08-05 9:32 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $14.5 | 442,851 (Direct) | View |
| 2026-07-01 Exercise | 2026-07-02 9:33 pm | N/A 2033-09-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $0 | 450,351 (Direct) | View |
| 2026-07-01 Exercise | 2026-07-02 9:33 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $14.5 | 450,351 (Direct) | View |
| 2026-07-01 Exercise | 2026-07-02 9:33 pm | N/A 2034-10-01 | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 8,334 | $0 | 305,000 (Direct) | View |
| 2026-07-01 Exercise | 2026-07-02 9:33 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 8,334 | $27.46 | 305,000 (Direct) | View |
| 2026-06-25 Exercise | 2026-06-26 9:31 pm | N/A 2033-09-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 15,000 | $0 | 457,851 (Direct) | View |
| 2026-06-25 Exercise | 2026-06-26 9:31 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 15,000 | $14.5 | 457,851 (Direct) | View |
| 2026-06-23 Conversion | 2026-06-23 9:56 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Fairmount Healthcare Fund II L.P. Kiselak Tomas Harwin Peter Evan Director | 683,347 | $0 | 1,158,121 (Indirect) | View |
| 2026-06-03 Exercise | 2026-06-03 9:32 pm | N/A 2034-10-01 | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 8,333 | $0 | 313,334 (Direct) | View |
| 2026-06-03 Exercise | 2026-06-03 9:32 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 8,333 | $27.46 | 313,334 (Direct) | View |
| 2026-06-01 Exercise | 2026-06-03 9:30 pm | N/A 2033-09-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $0 | 472,851 (Direct) | View |
| 2026-06-01 Exercise | 2026-06-03 9:30 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $14.5 | 472,851 (Direct) | View |
| 2026-05-27 Option Award | 2026-05-29 5:58 pm | N/A 2036-05-27 | Spyre Therapeutics Inc. | SYRE | Fairmount Funds Management LLC Kiselak Tomas Fairmount Healthcare Fund II L.P. Director | 8,026 | $0 | 8,026 (Indirect) | View |
| 2026-05-27 Option Award | 2026-05-29 5:56 pm | N/A 2036-05-27 | Spyre Therapeutics Inc. | SYRE | Albers Jeffrey W. Director | 8,026 | $0 | 8,026 (Direct) | View |
| 2026-05-27 Option Award | 2026-05-29 5:55 pm | N/A 2036-05-27 | Spyre Therapeutics Inc. | SYRE | HENDERSON MICHAEL THOMAS Director | 8,026 | $0 | 8,026 (Direct) | View |
| 2026-05-27 Option Award | 2026-05-29 5:55 pm | N/A 2036-05-27 | Spyre Therapeutics Inc. | SYRE | Stelzer Laurie Director | 8,026 | $0 | 8,026 (Direct) | View |
| 2026-05-27 Option Award | 2026-05-29 5:55 pm | N/A 2036-05-27 | Spyre Therapeutics Inc. | SYRE | McKenna Mark C. Director | 8,026 | $0 | 8,026 (Direct) | View |
| 2026-05-27 Option Award | 2026-05-29 5:54 pm | N/A 2036-05-27 | Spyre Therapeutics Inc. | SYRE | Milligan Sandra Director | 8,026 | $0 | 8,026 (Direct) | View |
| 2026-05-01 Exercise | 2026-05-01 9:35 pm | N/A 2033-09-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 12,500 | $0 | 480,351 (Direct) | View |
| 2026-05-01 Exercise | 2026-05-01 9:35 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 12,500 | $14.5 | 480,351 (Direct) | View |
| 2026-05-01 Exercise | 2026-05-01 9:34 pm | N/A 2034-10-01 | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 78,333 | $0 | 321,667 (Direct) | View |
| 2026-05-01 Exercise | 2026-05-01 9:34 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 78,333 | $27.46 | 321,667 (Direct) | View |
| 2026-04-01 Exercise | 2026-04-03 9:30 pm | N/A 2035-01-15 | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 7,958 | $0 | 87,542 (Direct) | View |
| 2026-04-01 Exercise | 2026-04-03 9:30 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 7,958 | $21.66 | 87,542 (Direct) | View |
| 2026-04-01 Exercise | 2026-04-03 9:29 pm | N/A 2033-09-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $0 | 492,851 (Direct) | View |
| 2026-04-01 Exercise | 2026-04-03 9:29 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 7,500 | $14.5 | 492,851 (Direct) | View |
| 2026-03-03 Exercise | 2026-03-03 9:32 pm | N/A 2033-09-01 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 2,500 | $0 | 500,351 (Direct) | View |
| 2026-03-03 Exercise | 2026-03-03 9:32 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 2,500 | $14.5 | 500,351 (Direct) | View |
| 2026-01-21 Other | 2026-01-23 9:31 pm | N/A N/A | Spyre Therapeutics Inc. | SYRE | HENDERSON MICHAEL THOMAS Director | 63,227 | $0 | 231,833 (Direct) | View |
| 2026-01-09 Option Award | 2026-01-13 9:27 pm | N/A 2036-01-09 | Spyre Therapeutics Inc. | SYRE | Burrows Scott L Chief Financial Officer | 140,000 | $0 | 140,000 (Direct) | View |
| 2026-01-09 Option Award | 2026-01-13 9:27 pm | N/A 2036-01-09 | Spyre Therapeutics Inc. | SYRE | Turtle Cameron Chief Executive Officer | 528,000 | $0 | 528,000 (Direct) | View |
| 2026-01-09 Option Award | 2026-01-13 9:26 pm | N/A 2036-01-09 | Spyre Therapeutics Inc. | SYRE | Sloan Sheldon Chief Medical Officer | 140,000 | $0 | 140,000 (Direct) | View |
| 2026-01-09 Option Award | 2026-01-13 9:25 pm | N/A 2036-01-09 | Spyre Therapeutics Inc. | SYRE | King-Jones Heidy See Remarks | 140,000 | $0 | 140,000 (Direct) | View |